 Proto-Oncogene Proteins
"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 7 | 0 | 7 | | 1994 | 4 | 1 | 5 | | 1995 | 3 | 3 | 6 | | 1996 | 4 | 5 | 9 | | 1997 | 8 | 3 | 11 | | 1998 | 1 | 1 | 2 | | 1999 | 4 | 3 | 7 | | 2000 | 10 | 3 | 13 | | 2001 | 6 | 2 | 8 | | 2002 | 5 | 7 | 12 | | 2003 | 10 | 9 | 19 | | 2004 | 15 | 14 | 29 | | 2005 | 9 | 9 | 18 | | 2006 | 8 | 4 | 12 | | 2007 | 3 | 1 | 4 | | 2008 | 5 | 6 | 11 | | 2009 | 8 | 3 | 11 | | 2010 | 5 | 9 | 14 | | 2011 | 8 | 6 | 14 | | 2012 | 8 | 8 | 16 | | 2013 | 15 | 10 | 25 | | 2014 | 11 | 9 | 20 | | 2015 | 4 | 3 | 7 | | 2016 | 6 | 3 | 9 | | 2017 | 5 | 5 | 10 | | 2018 | 13 | 7 | 20 | | 2019 | 8 | 2 | 10 | | 2020 | 3 | 4 | 7 | | 2021 | 6 | 5 | 11 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Szwarc MM, Guarnieri AL, Joshi M, Duc HN, Laird MC, Pandey A, Khanal S, Dohm E, Bui AK, Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. FAM193A is a positive regulator of p53 activity. Cell Rep. 2023 03 28; 42(3):112230.
-
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discov. 2023 03 01; 13(3):598-615.
-
Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
-
Gilani A, Siddiq Z, Kissell E, Kasson J, Kleinschmidt-DeMasters BK. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma. Childs Nerv Syst. 2023 Jul; 39(7):1861-1868.
-
Pietras EM, DeGregori J. Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis. Cancer Discov. 2022 10 05; 12(10):2234-2236.
-
Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
-
Tyler LC, Le AT, Chen N, Nijmeh H, Bao L, Wilson TR, Chen D, Simmons B, Turner KM, Perusse D, Kasibhatla S, Christiansen J, Dudek AZ, Doebele RC. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC. Thorac Cancer. 2022 Nov; 13(21):3032-3041.
-
Schleicher WE, Pietras EM. Reduced PU.1 Expression Collaborates with Tet2 Loss to Trigger Myeloid Leukemogenesis. Blood Cancer Discov. 2022 09 06; 3(5):378-381.
-
Bang TJ, Hu J, Patil T, Bar?n AE, Gao D, Yang JC, Kuo HY, Huang HC, Sachs PB, Camidge DR. The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). Clin Lung Cancer. 2022 Dec; 23(8):e501-e509.
-
Dziadziuszko R, Hung T, Wang K, Choeurng V, Drilon A, Doebele RC, Barlesi F, Wu C, Dennis L, Skoletsky J, Woodhouse R, Li M, Chang CW, Simmons B, Riehl T, Wilson TR. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. Mol Oncol. 2022 05; 16(10):2000-2014.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|